Search results
Accelerate therapeutic discovery and maximize ROI with our streamlined platform, fully integrated across your entire portfolio. Use digital and decentralized trials to scale your pipeline beyond what's possible with traditional clinical trials.
Join leading clinical experts as they discuss and debunk the top 5 myths about eCOA in 2025, separating fact from fiction to help clinical operations, procurement, and data management teams make smarter, faster decisions.
Explore the prevalent challenges encountered in eCOA clinical trials, from technical issues and patient adherence to data security and regulatory adherence, and discover strategies for mitigation.
What is eCOA?As FDA Principal Deputy Commissioner Janet Woodcock said in a 2015 Clinical Outcome Assessment Public Workshop, “It turns out that what is really bothering the patient and what is really bothering the doctor can be radically different things...patients are true experts in their disease.”Clinical outcome assessments (COAs) have been key to capturing a comprehensive picture of patient experiences and treatment outcomes in today’s research landscape for decades. Integrating COAs into trial protocols bolsters our treatments' scientific integrity and enhances our ability to understand the real impact of interventions on patients. COAs (called eCOAs when captured electronically) are essential to understanding whether a drug reduces symptoms, improves patients’ quality of life, and improves their ability to perform activities they care about. Since the mid-2010s, electronic clinical solutions, like eCOA, have rapidly replaced their paper counterparts. Electronic Clinical Outcome Assessments comprise systematized digital methods for capturing patient-centered outcomes in clinical trials. These systems utilize validated electronic interfaces to collect, store, and analyze patient-reported data, clinician observations, and performance metrics.
Gain a quick overview of what top trends and topics dominated DIA 2023.
With the 14th annual DPHARM® wrapping up, we talked to our peers across the industry to find out what the big themes and takeaways were from this year’s conference.
Joe Dustin, VP/GM of eCOA and Annie Hesslewood, Site & Patient adoption lead at Medable host an open discussion with a panel of sites and CRAs to provide a candid assessment of how upcoming changes in the eCOA landscape can reduce burden on participants and sites to maximize the chance of success in clinical trials.
We sat down with Parexel's VP, Patient Innovation Center and Decentralized Trials, Rosamund Round, to see what our industry needs to do to improve diversity in clinical trials.
Medable’s Privacy Statement applies to your use of the Medable.com websites (the “Sites”) as well as certain Medable Services (the “Services”).
Medable’s Privacy Statement applies to your use of the Medable.com websites (the “Sites”) as well as certain Medable Services (the “Services”).
Discover how Medable helped digitize and standardize a client's participant pain body maps for a diabetic polyneuropathy trial.
Read the three major takeaways from this year's DIA.
Medable’s Privacy Statement applies to your use of the Medable.com websites (the “Sites”) as well as certain Medable Services (the “Services”).
A top-10 global pharmaceutical company aimed to address eCOA adherence and patient enrollment challenges faced by clinical trial sites and participants in Japan. Recognizing Japan’s distinct regulatory, cultural, and logistical landscape, the company partnered with Medable to develop an initiative to enhance the region’s patient and site experience.
This DBM App is the app and analytics platform for healthcare. Review the Medable DBM app Privacy Statement here.
The Financial Conflict of Interest Policy for Medable regarding Public Health Service funded research.
Learn the basics of digital medicine and how it's evolving with this blog.
See how customers have had success with Medable, our trial platform, and our teams.
Streamline your clinical trial and generate high-quality data with a #1 rated, easy-to-use platform, offered in over 60 countries and 120 languages. Book a demo to learn more.
You asked, we answered. Find out how long it takes to plan for your first eConsent implementation in clinical trials.
A top 10 pharmaceutical company looked to Medable to streamline participant burden and enhance site and team experience in oncology trials, while establishing a scalable template for future trials in oncology and other areas.
Learn what impacts the new European Medicine Regulatory Network recommendations paper means to your clinical trial operations.
Learn how Medable's eCOA (electronic clinical outcome assessment) solution was able to deliver >90% adherence and scalability for a top pharmaceutical weight management clinical trial.
Learn how we can help you navigate the complexities of clinical operations so that you can meet your study's milestones faster and easier.
This blog showcases how clinical trial technologies that were initially categorized as “DCT (Decentralized clinical trials)" have now become a standard part of how clinical trials operate today.
Medable worked with a top 5 pharma company to increase the safety of patients as anti-cancer treatments may cause pulmonary toxicity, ranging from asymptomatic radiological changes to respiratory failure, and is considered a common side effect.
This summary looks at DCT patient and caregiver preferences regarding eConsent, telehealth, wearables, and other digital technologies in the area of oncology. There are differences noted between age, gender, and specific types of cancers.
Consult directly with an award-winning Medable SME about your trial and discover how to enable faster, easier, clinical trials through patient-focused experiences. Chat about best practices in protocol design and digital standardization, learn how the latest FDA & EU guidelines will impact you, or see client use cases on cost and time savings.
Gain a complete understanding of patient screening, including how best to screen patients in decentralized clinical trials.
In this webinar, learn how top pharma are using novel innovations to drive greater speed, scale, and access in clinical research than ever before in this webinar hosted by Musaddiq Khan, Vice President of DCT Solutions at Medable.
See why many of the top pharma are focused on building the "next model" of clinical trial conduct using foundational platforms.
Learn how top pharma are using novel innovations to drive greater speed, scale, and access in clinical research than ever before in this webinar hosted by Musaddiq Khan, Vice President of DCT Solutions at Medable.
A top-10 global pharmaceutical company partnered with Medable for their pivotal Phase III diabetes study in the highly competitive market. Recognizing the inefficiencies in traditional study delivery and closeout processes, the company leveraged Medable’s expertise to accelerate timelines, enhance operational efficiency, and achieve a faster time to market for this high-profile therapy.
Learn how clinical trial data collecting is evolving and how Medable is supporting clients with this blog on evidence generation, clinical trial data, DHTs, sensors, wearables, and more.
Debunk the most prevalent electronic informed consent myths and reach a deeper understanding of decentralized clinical trials.
Gain a complete understanding of electronic clinical outcome assessments (eCOAs), including how to improve the data collection process and how to make COAs more patient-friendly.
Gain a partner that helps bring speed and savings to your trials with a single platform that scales to support your study and SMEs that are here for your needs from beginning to end.
The partnership between Medable, U.S. Renal Care, and the top ten pharmaceutical sponsor exemplifies the transformative power of Medable’s Total Consent solution in clinical trials. By overcoming common misconceptions around participant age, cost, and complexity, Medable’s platform proved to be a flexible, fast, and efficient solution for the elderly renal care population. U.S. Renal Care sought to use Medable’s Total Consent (Medable’s eConsent solution) for an investigator-initiated trial. The phase 4 trial, which was funded by a top 10 pharmaceutical company, sought to enroll elderly participants suffering from Anemia ESKD (End Stage Kidney Disease) across 476 site users. The trial would be managed by three central principal investigators (PIs).
See how a pharmaceutical company used data gathered during the informed consent process to pre-populate their site's systems, as well as their own.